In a phase-IB clinical trial for metastatic non-small cell lung carcinoma patients, the combination of local irradiation (4 Gy x 5) and escalating doses of NHS-IL2 (0.15 mg/kg, 0.30 mg/kg, and 0.45 mg/kg) administered intravenously over three consecutive days every three weeks resulted in long-term survival in two patients, one of whom achieved long-term tumor control. The gene discussed is IL2; the disease is neoplasm.